The hypochromic red cell: a new parameter for monitoring of iron supplementation during rhEPO therapy
The hypochromic red cell: a new parameter for monitoring of iron supplementation during rhEPO therapy
复制标题
低色素红细胞：rhEPO 治疗期间铁补充监测的新参数
DOI：
--
复制
发表时间：
1995
影响因子：
2.4
通讯作者：
L. Schaefer
中科院分区：
文献类型：
--
作者：
R. Schaefer;L. Schaefer
在 rhEPO 刺激的红细胞生成过程中，骨髓铁供应可能成为血红蛋白合成的速率限制。在本研究中，我们跟踪了接受 rhEPO 治疗的透析患者中血红蛋白缺乏红细胞的发生情况，将其作为缺铁性红细胞生成的参数。接受 rhEPO 治疗的铁超载患者显示出极低数量的低色素红细胞 (1%)，而缺铁患者的低色素亚群为 22%（正常范围 < 循环红细胞的 2.5%）。在rhEPO治疗之前，尽管有轻度缺铁（转铁蛋白饱和度：17%），但10名透析患者的低色素红细胞数量正常（2.1%）。一旦开始rhEPO（150 U/kg/周），治疗4周内低色素红细胞的百分比显着上升至15.3%。当治疗方案中添加静脉补铁（750 毫克/4 周）时，这种情况很容易逆转（静脉补铁 4 周后 5.5%）。总而言之，定量红细胞分析似乎是检测接受 rhEPO 治疗的透析患者缺铁性红细胞生成的可靠工具。
Bone marrow iron supply may become rate limiting for hemoglobin synthesis during rhEPO-stimulated erythropoiesis. In the present study we followed the occurrence of hemoglobin-deficient red cells as a parameter of iron-deficient erythropoiesis in rhEPO-treated dialysis patients. rhEPO-treated patients with iron overload displayed very low numbers of hypochromic red cells (1%), while those with iron-deficiency had a hypochromic subpopulation of 22% (normal range < 2.5% of circulating red cells). Prior to rhEPO treatment, 10 dialysis patients showed normal numbers of hypochromic red cells (2.1%), despite mild iron deficiency (transferrin saturation: 17%). Once rhEPO (150 U/kg/week) was started, the percentage of hypochromic red cells rose significantly to 15.3% within 4 weeks of therapy. This was readily reversed when intravenous iron (750 mg/4 weeks) was added to the therapeutic regimen (5.5% after 4 weeks of i.v. iron). Taken together, quantitative red cell analysis seems to be a reliable tool to detect iron-deficient erythropoiesis in rhEPO-treated dialysis patients.
皮下重组促红细胞生成素诱导的红细胞再生：铁充足受试者的缺铁性红细胞生成。
影响因子：
20.3
作者：
Brugnara,C;Chambers,LA;Malynn,E;Goldberg,MA;Kruskall,MS
通讯作者：
Kruskall,MS